



medmix technology

Dominik Vonier

Head of Drug Delivery

14 November 2023



*Providing innovative solutions to help people
live healthier and more confident lives*

Disclaimer and other important notes

This presentation contains forward-looking statements that are based on management's current assumptions and expectations concerning future developments, including but not limited to, projections of financial developments, market activities or future performance of products and solutions, which therefore contain certain risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results or performance to differ materially from the statements made in this presentation. These risks and other factors include, among others, general economic and geopolitical conditions, foreign exchange fluctuations, competitive product and pricing pressures, the effect of a pandemic or epidemic, a cyber event, a natural disaster or other force majeure, as well as regulatory developments and changes in tax regimes.

Alternative Performance Measures (APM)

All bridges from reported figures to APM can be found in the financial review of medmix' half-year report 2023 and all definitions of APM can be found in the APM section of medmix' annual report 2022.

medmix

Our aspiration, mission and vision

ASPIRATION

Be the global leader in high precision delivery devices for the healthcare, consumer & industrial end markets

MISSION

Provide innovative solutions to help millions of people live a healthier and more confident life


VISION

Deliver innovative, reliable and sustainable application solutions that contribute to a better world



medmix Key figures

Our key figures



medmix Business Structure

Our segments



HEALTHCARE

CONSUMER AND INDUSTRIAL


DRUG DELIVERY

SURGERY

DENTAL

INDUSTRY

BEAUTY



Award-winning,
proprietary injection
pen platform



Pioneer in **bone cement**
mixing devices



Gold standard in
dental mixing
devices



Leading in industrial
mixing and dispensing
device systems



Leading microbrush
specialist

Drug Delivery - Overview

Haselmeier, a medmix brand

- Strong growth since acquisition in 2020 – re-positioning towards higher volumes
- Expanding product portfolio and ramping-up production capabilities
- Establish Haselmeier as preferred partner for our customers and their patients
- New autoinjector platform PiccoJect™ with distinct competitive advantages
- D-Flex™ disposable pen, low investment, quick to market
- Portfolio ready for strong growth in obesity, growth disorders, biologics and biosimilars

Haselmeier Strategy: Complete and flexible offering

For our customers and their patients



Become the preferred partner for pen and autoinjector solutions

- Be the preferred partner for all complex solutions: nothing too complex or too small
- Focus on impactful and high-value indications, eg obesity, growth disorders, auto-immune



Leading specialist for highly customized solutions based on our technology platforms


- We offer a complete portfolio for **both standard and flexible solutions**
- We are the only full-service provider with locations in EU, US and India

Haselmeier Portfolio: Products and services


We cover all needs for our customers and their patients



Injection Pens



Autoinjectors



Digital Solutions



Services

Customization:
Design & Development


Regulatory Affairs &
Quality Support

Final Assembly &
Packaging

Platforms tailored to customer and patients' needs

Product Platforms

- Lower capital expenditure
- Lower development costs
- Faster time to market



Technology Platforms

- Flexible customization options
- Flexible financial models
- More flexible in regional sourcing



Focus on PiccoJect™ autoinjector

Why an autoinjector?

- Simplifies at-home injection
- Ready to use
- Patient ease-of-use
- Safe
- Exact dosing
- Ideal for GLP-1 and biologics



PiccoJect™ – Excellence through Simplicity

Promotion Video



To play the video please click on this link in our FIND OUT MORE section:

Fireside-chat from the UBS Swiss Equity Technology and Innovation Days, Nov 14, 2023 – Video PiccoJect

PiccoJect™ – Excellence through Simplicity

Next generation device with competitive USPs


● Important for customers

● Important for patients

8 Only 8 parts in total

Committed to sustainability

Connectivity enabled



Ergonomic shape and small size

Two audible clicks

Fast time to market and low capital expenditure

High patient preference for PiccoJect™

Confirmed by human factor studies

92%

overall preference
for PiccoJect™

83%

rated drug window
visibility as
superior

75%

preferred the wide
cross-section

96%

expressed very high
willingness for
daily use

Patient testimonials

Very easy,
it just
felt natural.

It is really easy,
since my stroke my
memory is really bad
and my tremor – there is
nothing that I can get
wrong, and you want
that from
a drug.

It was just
a nice amount
of pressure

Focus on D-Flex™

Unique disposable pen allowing only intended doses




One fixed or several fixed-doses in just one pen




Visual feedback during injection and at dose completion



Only the intended dose(s) can be set



Fast adaptation:
Only one part needs to be changed



Assisted injection to reduce necessary injection force



Connectivity option on request



Fast time to market and low capital expenditure

Q&A

Dominik Vonier
Head of Drug Delivery





Your Investor Relations Contact

James Amoroso

Investor Relations, medmix

Phone: +41 41 723 73 57

E-mail: investorrelations@medmix.com

medmix Group AG

Neuhofstrasse 20

6340 Baar

Switzerland